Apollomics Class A Stock Market Value
| APLM Stock | 17.92 0.07 0.39% |
| Symbol | Apollomics |
Will Biotechnology sector continue expanding? Could Apollomics diversify its offerings? Factors like these will boost the valuation of Apollomics. If investors know Apollomics will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Apollomics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (52.80) | Revenue Per Share | Quarterly Revenue Growth 2.623 | Return On Assets | Return On Equity |
The market value of Apollomics Class A is measured differently than its book value, which is the value of Apollomics that is recorded on the company's balance sheet. Investors also form their own opinion of Apollomics' value that differs from its market value or its book value, called intrinsic value, which is Apollomics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Apollomics' market value can be influenced by many factors that don't directly affect Apollomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Apollomics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Apollomics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Apollomics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Apollomics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Apollomics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Apollomics.
| 11/01/2025 |
| 01/30/2026 |
If you would invest 0.00 in Apollomics on November 1, 2025 and sell it all today you would earn a total of 0.00 from holding Apollomics Class A or generate 0.0% return on investment in Apollomics over 90 days. Apollomics is related to or competes with SeaStar Medical, Moleculin Biotech, Lunai Bioworks, Tharimmune, BioLineRx, GeoVax Labs, and Adlai Nortye. Apollomics is entity of United States. It is traded as Stock on NASDAQ exchange. More
Apollomics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Apollomics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Apollomics Class A upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 9.56 | |||
| Information Ratio | 0.001 | |||
| Maximum Drawdown | 44.38 | |||
| Value At Risk | (14.50) | |||
| Potential Upside | 17.08 |
Apollomics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Apollomics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Apollomics' standard deviation. In reality, there are many statistical measures that can use Apollomics historical prices to predict the future Apollomics' volatility.| Risk Adjusted Performance | 0.0147 | |||
| Jensen Alpha | 0.0409 | |||
| Total Risk Alpha | (0.60) | |||
| Sortino Ratio | 0.001 | |||
| Treynor Ratio | 0.159 |
Apollomics January 30, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0147 | |||
| Market Risk Adjusted Performance | 0.169 | |||
| Mean Deviation | 6.78 | |||
| Semi Deviation | 9.27 | |||
| Downside Deviation | 9.56 | |||
| Coefficient Of Variation | 13313.72 | |||
| Standard Deviation | 9.38 | |||
| Variance | 87.96 | |||
| Information Ratio | 0.001 | |||
| Jensen Alpha | 0.0409 | |||
| Total Risk Alpha | (0.60) | |||
| Sortino Ratio | 0.001 | |||
| Treynor Ratio | 0.159 | |||
| Maximum Drawdown | 44.38 | |||
| Value At Risk | (14.50) | |||
| Potential Upside | 17.08 | |||
| Downside Variance | 91.3 | |||
| Semi Variance | 85.86 | |||
| Expected Short fall | (7.28) | |||
| Skewness | (0.22) | |||
| Kurtosis | 2.07 |
Apollomics Class A Backtested Returns
Apollomics appears to be slightly risky, given 3 months investment horizon. Apollomics Class A secures Sharpe Ratio (or Efficiency) of 0.0875, which signifies that the company had a 0.0875 % return per unit of risk over the last 3 months. By analyzing Apollomics' technical indicators, you can evaluate if the expected return of 0.7% is justified by implied risk. Please makes use of Apollomics' Mean Deviation of 6.78, risk adjusted performance of 0.0147, and Downside Deviation of 9.56 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Apollomics holds a performance score of 6. The firm shows a Beta (market volatility) of 0.38, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Apollomics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Apollomics is expected to be smaller as well. Please check Apollomics' semi variance, and the relationship between the treynor ratio and daily balance of power , to make a quick decision on whether Apollomics' price patterns will revert.
Auto-correlation | 0.31 |
Below average predictability
Apollomics Class A has below average predictability. Overlapping area represents the amount of predictability between Apollomics time series from 1st of November 2025 to 16th of December 2025 and 16th of December 2025 to 30th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Apollomics Class A price movement. The serial correlation of 0.31 indicates that nearly 31.0% of current Apollomics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.31 | |
| Spearman Rank Test | 0.25 | |
| Residual Average | 0.0 | |
| Price Variance | 3.26 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Apollomics Correlation, Apollomics Volatility and Apollomics Performance module to complement your research on Apollomics. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Apollomics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.